financetom
Business
financetom
/
Business
/
Prince Harry settles lawsuit with Murdoch papers after apology
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Prince Harry settles lawsuit with Murdoch papers after apology
Jan 22, 2025 3:01 AM

LONDON, Jan 22 (Reuters) - Prince Harry has settled his

lawsuit against Rupert Murdoch's News Group Newspapers (NGN)

over alleged unlawful information gathering, his lawyer said on

Wednesday, after the start of a long-awaited trial was

unexpectedly delayed.

Harry, 40, the younger son of King Charles, was suing the

publisher of the Sun and the now-defunct News of the World at

the High Court in London, alleging NGN unlawfully obtained

private information about him from 1996 until 2011.

His lawyer said that a deal had been reached to settle the

lawsuit.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Buckle's Same-Store, Overall Net Sales Fall in May
Buckle's Same-Store, Overall Net Sales Fall in May
Jun 6, 2024
08:15 AM EDT, 06/06/2024 (MT Newswires) -- Buckle (BKE) reported Thursday a 7.6% decrease in comparable-store net sales at stores open at least one year during the four weeks ended June 3. Net sales for the fiscal month declined 8.2% to $82 million from $89.3 million a year ago, the company said. Price: 38.70, Change: +0.43, Percent Change: +1.12 ...
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA
Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA
Jun 6, 2024
08:14 AM EDT, 06/06/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Thursday that data from the investigational combination of bulevirtide 10 milligram with pegylated interferon alfa-2a, or PegIFN, was superior to investigational bulevirtide 10 mg monotherapy for the treatment of compensated chronic hepatitis delta virus infection. The company is evaluating the efficacy and safety of bulevirtide as monotherapy...
BRIEF-Cycle Pharmaceuticals Announces All-Cash Proposal To Acquire Vanda Pharmaceuticals For $8.00 Per Share
BRIEF-Cycle Pharmaceuticals Announces All-Cash Proposal To Acquire Vanda Pharmaceuticals For $8.00 Per Share
Jun 6, 2024
June 6 (Reuters) - Vanda Pharmaceuticals Inc ( VNDA ): * CYCLE PHARMACEUTICALS ANNOUNCES ALL-CASH PROPOSAL TO ACQUIRE VANDA PHARMACEUTICALS FOR $8.00 PER SHARE * CYCLE PHARMACEUTICALS LTD: PROPOSED DEAL REPRESENTING A TOTAL CASH CONSIDERATION OF $466 MILLION Source text for Eikon: Further company coverage: ...
Mubadala-backed Zamp to buy Starbucks brand rights, stores in Brazil
Mubadala-backed Zamp to buy Starbucks brand rights, stores in Brazil
Jun 6, 2024
SAO PAULO, June 6 (Reuters) - Brazilian restaurant chain operator Zamp has agreed to buy the rights to operate the Starbucks brand in the South American country, as well as some stores, for 120 million reais ($22.7 million), it said on Thursday. In a securities filing, Zamp said that the deal was signed with SouthRock, the company that currently owns...
Copyright 2023-2026 - www.financetom.com All Rights Reserved